UMEM Research Studies

A phase III randomized single blinded study that aims to compare the two analgesic protocols recommended by the NHLBI for treating Vaso-occlusive episodes in the Emergency Department.

A prospective, nonblinded, randomized controlled trial that aims to assess whether an FDA-approved rapid turnaround test (RTAT) for Neisseria gonorrheae and Chlamydia trachomatis infections will lead to more appropriate antibiotic prescription in the emergency department. 

A Phase 2 randomized, double-blinded, placebo-controlled multicenter study designed to evaluate BLD-2660 as add-on to standard of care (SOC) therapy in hospitalized subjects with recently diagnosed COVID-19 compared to SOC treatment. The study will include a Screening period, a Treatment period, and a Follow-up period.

A single-center, non-randomized, non-blinded feasibility study to evaluate the performance, safety and tolerability of the Percutaneous Ultrasound Gastrostomy (PUG) procedure that utilizes a novel device in conjunction with widely available ultrasound technology.

A multi-centered, double blinded clinical trial to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment in participants with Influenza A who are at risk of developing complications. 

A multi-centered, double blinded clinical trial to evaluate the efficacy/safety of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment in hospitalized participants with Influenza A.

A prospective, non blinded, non randomized trial conducted at the University of Maryland Medical Center Downtown Campus (UMMC) located in Baltimore, Maryland that aims to evaluate patient engagement in a program to monitor home pulse oximetry and development of symptoms for patients with or under investigation for infection with SARS-CoV-2. 

A randomized, double-blinded, placebo-controlled, adaptive phase 1/2/3 master protocol will assess the safety, tolerability, and efficacy of REGN10933+REGN10987 and REGN10989 in ambulatory patients with COVID-19. The multicenter conduct of this study will enable generalizable evidence of the safety, tolerability, and efficacy of these investigational mAbs for COVID-19.